Observational studyBMC infectious diseases2025
Factors associated with cryptococcal capsular antigen positivity among people living with HIV: a retrospective observational cohort study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with cryptococcal capsular antigen positivity among people living with HIV: a retrospective observational cohort study.BMC infectious diseases · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCryptococcosis, which is caused by Cryptococcus, is an aggressive fungal disease posing a high mortality risk among people living with HIV (PLHIV). However, factors associated with cryptococcal capsular antigen (CrAg) positivity among PLHIV remain unclear.
methodsWe recruited PLHIV from the Guangzhou Eighth People's Hospital between March 2018 and December 2019. Serum CrAg was qualitatively detected using Lateral Flow Assay. Fungal culture and pathological examinations were performed on cerebrospinal fluid. Chi-squared tests and multivariable logistic regression were used to identify factors associated with CrAg positivity.
resultsA total of 1478 PLHIV were included, among whom 297 (20.1%) were antiretroviral therapy-naïve (ART-naïve), 1181 (79.9%) were ART-experienced. The median baseline CD4 + T cell count was 43 cells/μl (interquartile range [IQR]:13-117). The overall CrAg positivity rate was 5.1%, with 94.7% of CrAg-positive individuals having baseline CD4 + counts ≤ 200 cells/μl. CrAg positivity was 6.4% among ART-naïve and 4.7% among ART-experienced PLHIV. Notably, within the ART-experienced group, CrAg-positive PLHIV displayed lower baseline and latest CD4 + T cell counts than those in CrAg-negative PLHIV. CrAg status was significantly associated with shorter ART duration (≤ 1 year vs. > 2 year: adjusted odds ratio [aOR], 2.53; 95% confidence interval [CI], 1.20-5.34. 1-2 year vs. > 2 year: 4.61, 2.10-10.12) and other OIs (2.56, 1.41-4.63) among ART-experienced PLHIV.
conclusionsA considerable CrAg positivity rate was observed among both ART-naïve and ART-experienced PLHIV. CD4 + T cell count ≤ 200 cells/μl, shorter ART duration, and presence of other opportunistic infections were all significantly associated with CrAg positivity. These findings support extending serum CrAg screening to all PLHIV with CD4 + counts ≤ 200 cells/μl, regardless of ART status, to improve early detection and reduce cryptococcosis-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.